Stockscreener 앱 받기
7.83
0.13%
0.010
전일 마감가:
$7.82
열려 있는:
$7.72
하루 거래량:
1.51M
Relative Volume:
0.88
시가총액:
$2.45B
수익:
$2.68B
순이익/손실:
$-184.45M
주가수익비율:
-11.51
EPS:
-0.6805
순현금흐름:
$229.23M
1주 성능:
-2.85%
1개월 성능:
-4.63%
6개월 성능:
-5.21%
1년 성능:
+9.05%
1일 변동 폭
$7.665
$7.84
1주일 범위
$7.665
$8.235
52주 변동 폭
$6.50
$9.475
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
명칭
Amneal Pharmaceuticals Inc
전화
908-947-3120
주소
400 Crossing Boulevard, 3rd Floor, Bridgewater
AMRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
7.83 | 2.45B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
147.38 | 64.91B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.16 | 43.33B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.66 | 42.36B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.38 | 17.72B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
294.28 | 12.42B | 2.99B | 1.21B | 1.13B | 25.06 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-06 | 개시 | Goldman | Buy |
| 2025-02-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-09-06 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | 업그레이드 | Goldman | Sell → Buy |
| 2020-12-14 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-12-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-07-27 | 개시 | Goldman | Sell |
| 2020-05-12 | 업그레이드 | Guggenheim | Sell → Neutral |
| 2019-12-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-07 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-21 | 업그레이드 | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-03-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | 다운그레이드 | SunTrust | Buy → Hold |
| 2018-08-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 개시 | Morgan Stanley | Overweight |
| 2018-06-22 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Amneal Pharmaceuticals Inc 주식(AMRX)의 최신 뉴스
Amneal Pharmaceuticals Secures $2.1 Billion in Loans - TipRanks
How does Amneal Pharmaceuticals Inc. compare to its industry peersBest Dividend Report From AI Tools - jammulinksnews.com
What makes Amneal Pharmaceuticals Inc. stock price move sharplyBreakout Stocks Tips For Beginners - jammulinksnews.com
How strong is Amneal Pharmaceuticals Inc. company’s balance sheetMarket Forecast Signals For Fast Growth - jammulinksnews.com
What is Amneal Pharmaceuticals Inc. company’s growth strategyBreakout Stocks Strategy With Low Risk - jammulinksnews.com
Truist Financial Maintains a Buy on Amneal Pharmaceuticals (AMRX) With an $8 PT - Insider Monkey
Amneal Launches GLP-1 Agonist Exenatide Injection - Specialty Pharmacy Continuum
Teva Drops Inhaler Patent Infringement Lawsuit Against Amneal - Bloomberg Law News
Is Amneal Pharmaceuticals Inc. a candidate for recovery playReversal Alert Based on RSI Indicator Confirmed - metal.it
Amneal Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SayStock Market Watch With Alerts Shows Unusual Activity - metal.it
Teva, Amneal End Case Over Listing Inhaler IP In Orange Book - Law360
Why Amneal Pharmaceuticals Inc. stock attracts strong analyst attentionAI Driven Stock Trend Forecast Shows Momentum Shift - metal.it
Amneal (AMRX) is an Incredible Growth Stock: 3 Reasons Why - sharewise.com
Wall Street Analysts Think Amneal (AMRX) Could Surge 43.82%: Read This Before Placing a Bet - Zacks Investment Research
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Q1 Earnings Highlights: Amneal, ANI, Amphastar, and ViatrisNews and Statistics - IndexBox
Q1 Earnings Highs And Lows: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks - Yahoo Finance
Published on: 2025-07-29 09:45:24 - metal.it
Published on: 2025-07-28 20:38:28 - metal.it
Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
What are the technical indicators suggesting about Amneal Pharmaceuticals Inc.Capitalize on momentum stocks early - jammulinksnews.com
Is Amneal Pharmaceuticals Inc. a growth stock or a value stockAchieve consistent profits with smart trading - jammulinksnews.com
What institutional investors are buying Amneal Pharmaceuticals Inc. stockExceptional earning trajectories - jammulinksnews.com
How does Amneal Pharmaceuticals Inc. generate profit in a changing economyUnlock high-yield investment opportunities - jammulinksnews.com
How many analysts rate Amneal Pharmaceuticals Inc. as a “Buy”Achieve rapid financial growth with expert picks - jammulinksnews.com
How Amneal Pharmaceuticals Inc. stock performs during market volatilityFree Stock Selection with 300% Return - metal.it
Truist Financial Sticks to Its Buy Rating for Amneal Pharmaceuticals (AMRX) - The Globe and Mail
Amneal Pharmaceuticals Inc. Stock Analysis and ForecastMassive portfolio appreciation - PrintWeekIndia
What drives Amneal Pharmaceuticals Inc. stock priceFree Investment Community - PrintWeekIndia
Amneal Pharmaceuticals Prices $600M Senior Notes Offering - MSN
Truist Financial Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Announces Target Price $8 - 富途牛牛
Is Amneal Pharmaceuticals Inc. a good long term investmentPowerful profit generation - PrintWeekIndia
Amneal Pharmaceuticals prices $600 million in senior secured notes, increases term loan - Investing.com Nigeria
What analysts say about Amneal Pharmaceuticals Inc. stockFree Investment Community - Autocar Professional
Amneal Pharmaceuticals prices $600 million in senior secured notes, increases term loan By Investing.com - Investing.com South Africa
Why Investors Shouldn't Be Surprised By Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Low P/S - simplywall.st
Amneal Announces Proposed Refinancing of Existing Credit - GlobeNewswire
Amneal Pharmaceuticals Inc (AMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.80%
자본화:
|
볼륨(24시간):